Advertisement

The Lead

NICE Draft Guidance Rejects Sanofi's Zaltrap

June 21, 2013 10:01 am | by Matthew Dennis | News | Comments

The National Institute for Health and Care Excellence issued draft guidance recommending against NHS reimbursement of Sanofi's Zaltrap (aflibercept) for treating patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen. The drug was approved for this use in Europe in February.

NICE Provisionally Rejects Bristol-Myers Squibb's Yervoy

October 14, 2011 5:01 am | by Matthew Dennis | News | Comments

The National Institute for Health and Clinical Excellence issued draft guidance rejecting NHS...

NICE Provisionally Rejects Eisai's Breast Cancer Drug Halaven

July 20, 2011 5:41 am | by Matthew Dennis | News | Comments

The National Institute for Health and Clinical Excellence released draft guidance Wednesday,...

Vidaza Receives Positive Final Appraisal Determination from NICE

February 18, 2011 4:17 am | Product Releases | Comments

Celgene today announced that the National Institute for Health and Clinical Excellence (NICE) has...

View Sample

FREE Email Newsletter

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading